Our Pipeline

Pioneering Treatment Options for Food Allergies and Beyond

The information contained here is under clinical investigation. Neither any product nor the technology have been approved for any use or marketing by regulatory authorities in any country.

Using our innovative VIASKIN® patch technology, we are committed to developing a pipeline of food allergy product candidates that could potentially transform the care of food-allergic patients. Thank you to all of the patients, caregivers, collaborating physicians and research staff who have enabled our clinical trial development and helped us to advance the potential of the VIASKIN® patch.

Development Pipeline

PROGRAM & INDICATION
DEVELOPMENT STAGE
Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3
Food Allergy
VIASKIN® peanut patch
(DBV712)
Peanut Allergy
Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3
Ages 1-3 years and 4-7 years
Ages 1-3 years
Ages 4-7 years
Ages 4-11 years
Food Allergy
VIASKIN® milk patch
(DBV135)
Cow's Milk Allergy
Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3
Ages 2-17 years
Food Allergy
VIASKIN® milk patch
Eosinophilic Esophagitis*
Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3
Ages 4-17 years
Autoimmune & Inflammatory Disorders
Multiple Programs
Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3
Vaccines
Multiple Programs
Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3

*Early-stage development based on studies with VIASKIN® milk patch for cow’s milk allergy

Food Allergy Clinical Trials

DBV has designed a robust clinical development program that includes investigation of VIASKIN® peanut patch (DBV712) and VIASKIN® milk patch (DBV135).

VIASKIN® Peanut Patch Clinical Trials

Peanut allergy is one of the most common food allergies and can cause severe, potentially fatal, allergic reactions, as well as anaphylaxis. DBV has advanced a comprehensive clinical research program across age groups for the VIASKIN® peanut patch, including the completed EPITOPE Phase 3 clinical trial in 1 – 3-year-olds, and ongoing VITESSE Phase 3 clinical trial in 4 – 7-year-olds.

Learn more about the trial

* VIASKIN® peanut patch is an investigational product and has not been approved for any use in any country.

VIASKIN® Milk Patch Clinical Trials

Cow’s Milk Protein Allergy (CMPA) mainly appears in the first year of life and affects approximately 2-3 percent of the population in developed countries. We completed a Phase 1/2 trial to study the safety and efficacy of VIASKIN® milk patch in pediatric and adolescent patients.
Learn more about the trial

*VIASKIN® milk patch is an investigational product and has not been approved for any use in any country.

Other Early Stage Development Programs

Investigations Beyond Food Allergies

DBV is investigating other areas of significant unmet medical need, including eosinophilic esophagitis (EoE), inflammatory conditions and autoimmune diseases, as well as the potential application of the technology behind the VIASKIN® patch to vaccines.

Learn more about the trial
Scroll to Top